Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
Conditions
Interventions
Patritumab Deruxtecan
Platinum-based chemotherapy
Locations
182
United States
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States
Highlands Oncology
Springdale, Arkansas, United States
City of Hope
Duarte, California, United States
Moores Cancer Center at the UC San Diego Health
La Jolla, California, United States
Scripps MD Anderson Cancer Center
La Jolla, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Start Date
July 8, 2022
Primary Completion Date
May 31, 2024
Completion Date
June 30, 2026
Last Updated
January 31, 2025
NCT06659458
NCT06053099
NCT05263947
NCT04716933
NCT05153408
NCT01532089
Lead Sponsor
Daiichi Sankyo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions